1. Next-Gen Psoriasis Therapies:

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Psoriasis Basics

4. Pathogenesis of Psoriasis

5. Pathogenesis of Psoriasis TNF-α

6. Pathogenesis of Psoriasis Interleukins

7. Targeted Agents for Psoriasis

8. PDE4 Inhibitor

9. IL-17 and IL-17 Receptor Blockers

10. IL-23 Blockers

11. JAK Inhibitors

12. Psoriasis Treatment and Its Effect on Outcomes: Efficacy

13. Safety Considerations IL-17 Inhibition

14. Safety Considerations IL-12 and IL-23 Inhibition

15. Newer Biologics Have Less Toxicity Compared With Older Systemic Agents

16. Who Would Benefit From Newer Targeted Agents?

17. Who Would Benefit From Newer Targeted Agents? (cont)

18. Who Would Benefit From Newer Targeted Agents? (cont)

19. Who Would Benefit From Newer Targeted Agents? (cont)

20. Who Would Benefit From Newer Targeted Agents? (cont)

21. Psoriasis and Cardiovascular Disease

22. Other Potential Considerations

23. Other Potential Considerations (cont)

24. Concluding Remarks

25. Abbreviations

26. Abbreviations (cont)